GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Naloxegol tablets (Movantik, adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Movantik

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
MOVANTIK: renal starting dose and conditional escalation

The higher dose is a conditional option after tolerance and inadequate response, not the default renal maintenance dose. CYP3A interactions can impose additional restrictions.

Before applying: Check the renal starting dose and interaction pathway before considering escalation.

Also check: MOVANTIK: renal starting dose and conditional escalation

Official source

Naloxegol tablets (Movantik, adults) - selected U.S. label sections

Product / population
Adult MOVANTIK oral tablets for opioid-induced constipation.
Renal measure
Creatinine clearance in mL/min

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal starting dose and cautious escalation

For CrCl below 60 mL/min, including severe or end-stage impairment, start 12.5 mg once daily. If well tolerated but constipation persists, the label permits increasing to 25 mg once daily after considering increased exposure and adverse-reaction risk. Mild impairment does not require adjustment.

Dialysis and other cautions

The renal starting recommendation is not replaced with a larger dose solely because the patient receives hemodialysis. Review the contraindications, CYP3A interactions and gastrointestinal warnings separately.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Naloxegol tablets (Movantik, adults) - selected U.S. label sections

Adult MOVANTIK oral tablets for opioid-induced constipation.

Renal method: Creatinine clearance in mL/min
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - MOVANTIK

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Naloxegol - MOVANTIK tablets; selected source sections, not a full prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

MOVANTIK: renal starting dose and conditional escalation

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dose table scope

MOVANTIK: renal starting dose and conditional escalation

The higher dose is a conditional option after tolerance and inadequate response, not the default renal maintenance dose. CYP3A interactions can impose additional restrictions.

How to use this: Check the renal starting dose and interaction pathway before considering escalation.

GlobalRPh RX List - MOVANTIKNaldemedine - SYMPROIC tablets

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeNaloxegol tablets (Movantik, adults) - selected U.S. label sectionsGlobalRPh RX List - MOVANTIK
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635

Product and population scope

Adult MOVANTIK oral tablets for opioid-induced constipation.

RDM32-naloxegol-movantik-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Naloxegol tablets (Movantik, adults) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult MOVANTIK oral tablets for opioid-induced constipation.

Renal method: Creatinine clearance in mL/min
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal starting dose and cautious escalation

For CrCl below 60 mL/min, including severe or end-stage impairment, start 12.5 mg once daily. If well tolerated but constipation persists, the label permits increasing to 25 mg once daily after considering increased exposure and adverse-reaction risk. Mild impairment does not require adjustment.

RDM32-naloxegol-movantik-1 · Source locator: 2.3; 8.6

Dialysis and other cautions

The renal starting recommendation is not replaced with a larger dose solely because the patient receives hemodialysis. Review the contraindications, CYP3A interactions and gastrointestinal warnings separately.

RDM32-naloxegol-movantik-2 · Source locator: 2.3; 4; 5; 7; 12.3

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635
Retrieved
2026-09-05
DailyMed Set ID
300a6474-ebcd-4404-8040-48fdcfcc1635
Renal-function method
Creatinine clearance in mL/min
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
eb10009fdf07e972254a1e962d929e616ccafbbcc7f96c3c7cb3e54316f7dd27
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - MOVANTIK

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Naloxegol - MOVANTIK tablets; selected source sections, not a full prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage.
Source date: RX page prints August 2017.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At CrCl <60 mL/min, including moderate, severe or end-stage impairment, start 12.5 mg once daily. If tolerated but constipation persists, the source permits escalation to 25 mg once daily while considering markedly increased exposure and adverse reactions in some renally impaired patients. Mild impairment needs no adjustment. Hemodialysis was ineffective for elimination. Strong CYP3A inhibitors are contraindicated; avoid moderate inhibitors or retain 12.5 mg with monitoring when unavoidable. This conditional escalation must not become an automatic maintenance dose.

RDM48-rxlist-naloxegol-movantik-6488c07722-C1 · Source locator: Adult renal dosage, lines 53-58; renal pharmacokinetics and overdose.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/movantik-drug/
Retrieved
2026-09-08
Renal-function method
Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage.
Source date/version
RX page prints August 2017.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
8adbbf71bc9f3c6b36fc1d17349200b744c544a13163047ef4390283897dba1d

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
39776c43a31d08f7f61bb29592dfd24b7d7489a002caf3308b84c884d784d4de
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report